SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY

被引：0
|
作者：
Foster, G. R. [1 ]
Pol, S. [2 ,3 ]
Aerssens, J. [4 ]
Zeuzem, S. [5 ]
Andreone, P. [6 ]
Lawitz, E. J. [7 ]
Roberts, S. [8 ]
Younossi, Z. [9 ]
Focaccia, R. [10 ]
Horban, A. [11 ]
Pockros, P. J. [12 ,13 ]
Van Heeswijk, R. [4 ]
de Meyer, S. [4 ]
Luo, D. [14 ]
Beumont, M. [4 ]
Picchio, G. [14 ]
机构：
[1] Queen Mary Univ London, Inst Cell & Mol Sci, London, England
[2] Univ Paris 05, INSERM, U567, Paris, France
[3] Cochin Hosp, Assistance Publ Hop Paris, Paris, France
[4] Tibotec BVBA, Beerse, Belgium
[5] Goethe Univ Frankfurt, Med Ctr, D-60054 Frankfurt, Germany
[6] Univ Bologna, Bologna, Italy
[7] Alamo Med Res Ltd, San Antonio, TX USA
[8] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[9] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA
[10] Emilio Ribas Infect Dis Inst, S O Paulo, Brazil
[11] Med Univ Warsaw, Warsaw, Poland
[12] Scripps Clin, La Jolla, CA 92037 USA
[13] Scripps Res Inst, La Jolla, CA 92037 USA
[14] Tibotec Inc, Titusville, NJ USA
来源：
GUT | 2011年 / 60卷
关键词：
D O I：
10.1136/gutjnl-2011-300857b.12
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP12
引用
收藏
页码：A55 / A55
页数：1
相关论文
共 13 条
  • [1] SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY
    Pol, S.
    Aerssens, J.
    Zeuzem, S.
    Andreone, P.
    Lawitz, E. J.
    Roberts, S.
    Younossi, Z.
    Foster, G. R.
    Focaccia, R.
    Horban, A.
    Pockros, P. J.
    Van Heeswijk, R.
    de Meyer, S.
    Luo, D.
    Botfield, M.
    Beumont, M.
    Picchio, G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S6 - S7
  • [2] Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-Responder Patients Treated With Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the Realize Study
    Younossi, Zobair M.
    Aerssens, Jeroen
    Pol, Stanislas
    Pockros, Paul
    Lawitz, Eric J.
    Zeuzem, Stefan
    Andreone, Pietro
    Roberts, Stuart K.
    Foster, Graham
    Focaccia, Roberto
    Horban, Andrzej
    van Heeswijk, Roll
    De Meyer, Sandra
    Luo, Don
    Botfield, Martyn C.
    Beumont-Mauviel, Maria
    Picchio, Gaston
    GASTROENTEROLOGY, 2011, 140 (05) : S907 - S908
  • [3] SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY
    Muellhaupt, Beat
    Pol, Stanislas
    Aerssens, Jeroen
    Zeuzem, Stefan
    Andreone, Pietro
    Lawitz, Eric J.
    Roberts, Stuart
    Younossi, Zobair
    Foster, Graham R.
    Focaccia, Roberto
    Horban, Andrzej
    Pockros, Paul J.
    Van Heeswijk, Rolf
    de Meyer, Sandra
    Luo, Donghan
    Beumont, Maria
    Picchio, Gaston
    SWISS MEDICAL WEEKLY, 2011, 141 : 6S - 7S
  • [4] 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL
    Bronowicki, J-P
    Hezode, C.
    Bengtsson, L.
    Pol, S.
    Bourliere, M.
    Serfaty, L.
    de Ledinghen, V.
    Tran, A.
    Benhamou, Y.
    Grange, J-D
    Mathurin, P.
    Marcellin, P.
    Trepo, C.
    Zarski, J-P
    Seepersaud, S.
    Kelliher, K.
    Botfield, M.
    Pawlotsky, J-M
    JOURNAL OF HEPATOLOGY, 2012, 56 : S430 - S431
  • [5] ALL IL28B GENOTYPES HAVE HIGH SVR RATES IN PATIENTS TREATED WITH VX-222 IN COMBINATION WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN IN THE ZENITH STUDY
    Penney, M. S.
    De Souza, C.
    Seepersaud, S.
    Alves, K.
    Koziel, M. J.
    Kauffman, R. S.
    Di Bisceglie, A. M.
    Botfield, M. C.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S476 - S477
  • [6] PRE-TREATMENT IP-10 LEVELS AND IL28B GENOTYPE IN PREDICTION OF SVR IN PRIOR TREATMENT-EXPERIENCED GENOTYPE 1 HCV PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/ RIBAVIRIN IN THE REALIZE STUDY
    Vijgen, L.
    Talloen, W.
    Scholliers, A.
    Johansson, S.
    Tuefferd, M.
    De Meyer, S.
    Witek, J.
    Fanning, G.
    Picchio, G.
    Pol, S.
    Zeuzem, S.
    Aerssens, J.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S462 - S462
  • [7] LOW RATES OF SVR TO PEGINTERFERON PLUS RIBAVIRIN IN HCV GENOTYPE 1 IL28B RS12979860 CC CIRRHOTIC PATIENTS WITHOUT RAPID VIROLOGICAL RESPONSE
    Degasperi, E.
    Aghemo, A.
    Galmozzi, E.
    Valenti, L.
    Rumi, M. G.
    De Francesco, R.
    De Nicola, S.
    Soffredini, R.
    Colombo, M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S425 - S425
  • [8] Pre-treatment IP-10 levels and IL28B genotype as predictive markers for SVR in treatment-naive patients with genotype 1 HCV infection treated with telaprevir/peginterferon/ribavirin in the OPTIMIZE study
    Vijgen, Leen
    Dierynck, Inge
    Janssen, Katrien
    Talloen, Willem
    Gys, Luc
    Vanhoof, Greet
    Luo, Donghan
    De Meyer, Sandra
    Witek, James
    Aerssens, Jeroen
    HEPATOLOGY, 2013, 58 : 1096A - 1097A
  • [9] IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naive and treatment-experienced patients other than prior partial- and null-responders
    Calisti, Giorgio
    Tavares, Amanda
    Macartney, Malcolm J.
    McCormick, Adele
    Labbett, Wendy
    Jacobs, Michael
    Dusheiko, Geoffrey
    Rosenberg, William M.
    Haque, Tanzina
    SPRINGERPLUS, 2015, 4
  • [10] GS-5885+GS-9451+PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAIVE GENOTYPE 1 IL28B CC PATIENTS
    Thompson, A.
    Han, S.
    Shiffman, M. L.
    Rossaro, L.
    Ghalib, R.
    Beavers, K.
    Pianko, S.
    Wu, X.
    Pang, P. S.
    Rossi, S.
    McHutchison, J.
    Muir, A.
    Lee, S.
    George, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S29 - S29
12